SCHEMBL7899569

SCHEMBL7899569

CCc1cccc(C(=O)N2CCc3ccccc3C2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
ALDH1A1 P00352 3/20 0.66
PARP1 P09874 1/20 0.59
CYP2C19 P33261 3/20 0.56
CYP3A4 P08684 2/20 0.56
CYP2D6 P10635 1/20 0.56
HSP90AA1 P07900 2/20 0.56
HSP90AB1 P08238 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
HTT P42858 3/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 1/20 0.55
ATM Q13315 1/20 0.55
TP53 P04637 1/20 0.55
CYP2C9 P11712 2/20 0.53
CYP1A2 P05177 1/20 0.53
LOX P28300 1/20 0.53
LOXL2 Q9Y4K0 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7904938 0.90 HSP90AA1 (0.53) HPGDSMN1; SMN2ALDH1A1HSP90AA1HSP90AB1
SCHEMBL10274436 0.90 HPGD (0.63) HPGDSMN1; SMN2ALDH1A1PARP1CYP2C19
SCHEMBL1690513 0.86 HPGD (0.62) HPGDSMN1; SMN2ALDH1A1PARP1CYP2C19
SCHEMBL8429770 0.85 HPGD (0.71) HPGDSMN1; SMN2ALDH1A1CYP2C19CYP3A4
SCHEMBL12846718 0.82 HPGD (0.71) HPGDSMN1; SMN2ALDH1A1CYP2C19CYP3A4
SCHEMBL14234095 0.81 ALDH1A1 (0.62) HPGDSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL13462844 0.81 PDE3B (0.53) HPGDSMN1; SMN2ALDH1A1PARP1MEN1
SCHEMBL17320562 0.81 TP53 (0.54) HPGDSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4279383 0.80 HPGD (0.73) HPGDSMN1; SMN2ALDH1A1CYP2C19CYP3A4
SCHEMBL30277860 0.80 HPGD (0.73) HPGDSMN1; SMN2ALDH1A1CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166560-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-15 US disclosed
US-9617224-B2 Five-membered heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-04-11 US disclosed
EP-2373634-B1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARM CO LTD (JP) 2015-11-11 EP disclosed
US-20150259297-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-09-17 US disclosed
US-9079860-B2 Five-membered heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-07-14 US disclosed
US-8716492-B2 Five-membered heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-06 US disclosed
WO-2010065717-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166560-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 HPGD 1339/4885SMN1; SMN2 4322/4885ALDH1A1 4184/4885
US-20150259297-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 HPGD 1339/4885SMN1; SMN2 4322/4885ALDH1A1 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.